At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
In Brief
A Phase 2 clinical trial evaluating Paclitaxel and Trastuzumab for Breast Cancer and Carcinoma of the Breast. Completed, enrolled 406 participants across 20 sites.
Detailed Summary
The purpose of this study is to find out what effect the postoperative combination of therapies: trastuzumab (herceptin) and paclitaxel (taxol) will have on breast cancer recurrence. A combination of trastuzuamb and chemotherapy has been used in women with node positive and high risk node negative disease. This tests utilizes a well tolerated regimen of weekly paclitaxel and trastuzumab in women with T1, node negative tumors that are HER2 positive. We would like to determine how effective this drug combination is when used in women with early stage breast cancer, as well as to better define the side effects of this treatment.
Study Details
Timeline
Interventions
Every week for 12 weeks
Once a week for twelve weeks Then once a week or once every three weeks for 40 weeks